Biotechnology June 29, 2026 ‘There’s room for multiple winners’: Talawar Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset
Biotechnology May 6, 2026 Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion